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Alzheimer’s disease (AD) is the most common neurodegenerative disease in the elderly.
While advancements have been made in understanding the genetic and molecular basis
of AD, the clinical diagnosis of AD remains difﬁcult, and post-mortem conﬁrmation is often
required. Furthermore, the onset of neurodegeneration precedes clinical symptoms by
approximately a decade. Consequently, there is a crucial need for an early and accurate
diagnosis of AD, which can potentially lead to strategies that can slow down or stop the
progression of neurodegeneration and dementia. Recent advances in the non-coding RNA
ﬁeld have shown that microRNAs (miRNAs) can function as powerful biomarkers in human
diseases. Studies are emerging suggesting that circulating miRNAs in the cerebrospinal
ﬂuid and blood serum have characteristic changes in AD patients.Whether miRNAs can be
used in AD diagnosis, alone or in combination with other AD biomarkers (e.g., amyloid and
tau), warrants further investigation.
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INTRODUCTION
Alzheimer’s disease (AD) is a prevalent, devastating, and progres-
sive neurodegenerative disorder. Epidemiological studies predict
that over 35 million people worldwide will be affected by 2050,
thus signiﬁcantly increasing social and economical burdens. There
is no cure at hand, and only a few medications aimed at slowing
down memory deﬁcits and clinical symptoms are available, with
limited beneﬁts. Consequently, there is an urgent need for the
identiﬁcation of biomarkers that will allow the detection of AD at
early (prodromal) stages, potentially leading to novel diagnostic
or therapeutic strategies.
Pathologically, AD is characterized by the gradual, widespread
loss of neurons, synapses, and neuropil, culminating in ∼40%
loss of brain mass in end-stage disease (West et al., 1994; Gomez-
Isla et al., 1996). There are two main AD pathological hall-
marks: extracellular amyloid (senile) plaques and intracellular
neuroﬁbrillary tangles (NFTs; Hyman et al., 2012). The amy-
loid plaques comprise aggregated amyloid-beta (Aβ) peptides
that are generated by sequential cleavage of amyloid precursor
protein (APP) by β-secretase/BACE1 and the presenilin (PSEN)-
containing γ-secretase complex (Kang et al., 1987; Wolfe, 2006).
The NFTs result from the abnormal aggregation of hyperphos-
phorylated microtubule-associated protein, tau. The reason for
tau aggregation into tangles remains under investigation, but may
result from an imbalance in the delicate regulation of tau kinases
and phosphatases. Whereas approximately 1–5% of AD cases can
be explained genetically by mutations in APP or PSEN genes, the
exact cause(s) of sporadicADremains obscure.Most experts agree,
however, that sporadic AD is caused by a combination of genes
and environmental factors (multifactorial), perhaps exacerbated
by oxidative stress and inﬂammation.
Biomarkers are used to measure or indicate the effects or
progress of a disease or condition. A subtype of biomarkers relates
to speciﬁc and traceable biochemical molecules or compounds
found in body ﬂuids. Detection of these substances may indicate
disease states or allow correlations with the progression or the sus-
ceptibility to a disease or a given treatment. They can be measured
in, for instance, saliva, sweat, breath, blood/serum, urine, and cere-
brospinal ﬂuid (CSF). The collection of these biological ﬂuids is
signiﬁcantly less invasive than biopsies, an important and practical
issue when studying neurodegenerative disorders like AD.
Accumulating evidence suggests that circulating biomarkers
may be used inADdiagnosis, themost common beingAβ peptides
(Aβ40 and Aβ42, the latter being more prone to aggregation) and
tau/phospho-tau (Thr181 being one of the common phospho-
epitopes). While this area of research continues to progress
(Tarawneh and Holtzman, 2010; Holtzman, 2011), large variabil-
ity exists in the literature, hampering or delaying their routine
use in the clinic (Ingelson et al., 1999). Moreover, their potential
use as prodromal AD biomarkers remains uncertain. Therefore,
most experts agree that additional biomarkers are required for an
accurate and early diagnosis of AD vs. other potential causes of
dementia. In this review, we discuss recent studies suggesting that
miRNAs could function as novel, non-invasive biomarkers in AD.
miRNAs AS BIOMARKERS
The miRNAs are a class of small (∼22 nt) non-protein-coding
RNAs crucially involved in the post-transcriptional regulation
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of gene expression. They are important for multiple biological
processes such as development, proliferation, inﬂammation, and
apoptosis (Xu et al., 2004; Pasquinelli et al., 2005; Thounaojam
et al., 2013). The biogenesis and role(s) of the miRNA path-
way have been recently and thoroughly reviewed by Treiber et al.
(2012, and references therein). In brief,miRNAs function by bind-
ing with partial complementarity to messenger RNA (mRNA)
sequences, mainly in the 3′ untranslated region (3′UTR). This
targeting leads to either degradation or translational repression
of the mRNA template(s), causing an overall downregulation in
protein output. The miRNAs can target several disease-related
genes involved in neurodegeneration (Delay et al., 2012; Abe and
Bonini, 2013).
The precisemechanism(s) involved inmiRNA release fromcells
remain largely unknown, butmay involve the ceramide-dependent
secretory machinery (Kosaka et al., 2010). Alternatively, there may
be a passive leakage from necrotic or apoptotic cells (Zernecke
et al., 2009). In any case, these small RNAs are highly stable in
body ﬂuids such as plasma and CSF (Mraz et al., 2009), making
them attractive biomarkers. There are several factors involved in
modulating (distant) circulating miRNAs. These small RNAs are
transported in free forms, exosomes, liposomes, or high-density
lipoproteins, which protect them from degradation (Vickers et al.,
2011; Hu et al., 2012; the stable packaging, processing, and func-
tionality of miRNAs in bioﬂuids is a fascinating and important
area of research mostly beyond what is addressed in the current
review). While some miRNAs are ubiquitously expressed, others
are present in speciﬁc cells or tissues, including the central nervous
system (CNS; Landgraf et al., 2007). Furthermore, bioinformatics
studies suggest that miRNA abundance is directly correlated with
mRNA target activity (Dorval et al., 2012).
Interestingly, miRNAs have been described as epigenetic con-
tributors to age-related cognitive changes (Kosik et al., 2012). It
has been suggested that dysregulation of these miRNA-dependent
epigenetic functions in vulnerable brain regions may lead to cog-
nitive impairments. Accordingly, the past few years have witnessed
an explosion of papers linking miRNAs to disease states, and cur-
rent research efforts establish that miRNA expression proﬁles are
altered in a variety of pathogenic conditions. This is particularly
recognized in the cancer ﬁeld (Sayed and Abdellatif, 2011). Inter-
estingly, the various changes in miRNA levels are observable not
only in cells/tissues directly related to disease (e.g., tumors vs.
adjacent tissues), but often in the periphery or distant biological
systems (e.g., tumors vs. blood). It is noteworthy thatmost periph-
eral miRNAs are also found in the brain, albeit at various levels
(Hebert et al., 2013).
CIRCULATING miRNA BIOMARKERS IN AD
CEREBROSPINAL FLUID
Cerebrospinal ﬂuid is a clear ﬂuid that ﬂows within the ventri-
cles and around the surface of the brain and spinal cord. One
primary function of CSF is to circulate nutrients within the
CNS and, in turn, to act as a waste remover. The CSF is an
attractive source of biomarkers as it is in direct and constant
contact with the extracellular space of the brain, and can reﬂect
biochemical and/or physiological changes that occur inside the
brain.
In a pioneer study by Cogswell et al. (2008), the group per-
formed a large-scale expression analysis of miRNAs in control and
AD CSF. About 201 (out of 242 tested) miRNAs were detected
above background levels, as measured by quantitative reverse
transcriptase-polymerase chain reaction (qRT-PCR) using Taq-
Man probes (Applied Biosystems). They identiﬁed 60 miRNAs,
including let-7i, that were signiﬁcantly altered in AD CSF (Braak
V stage) when compared to healthy elderly controls (Braak I stage;
n = 10 per group, P< 0.05). Using biological pathway enrichment
algorithms, the group observed an association between misregu-
latedmiRNAs and the immune system, including pathways such as
innate immunity (e.g., miR-146b) and T cell activation and differ-
entiation (e.g., miR-181a, miR-142-5p). Putative targets for these
miRNAs include IRAK1, TRAF6 (Lindsay, 2008), and Bcl-2 fam-
ily members (Ouyang et al., 2012). The authors suggested that
abnormally expressedmiRNAs in the CSFwere likely derived from
immune cells. This was the ﬁrst study demonstrating thatmiRNAs
can be detected in the CSF (even when initially frozen) and are
altered in neurodegenerative disease conditions.
van Harten et al. (2011) conﬁrmed that it was technically fea-
sible to perform genome-wide expression analyses of circulating
miRNAs in control and AD CSF. The authors used two stem-loop
qRT-PCR methods, including: (1) an individual miRNA TaqMan
qRT-PCR and (2) a Megaplex modiﬁed microarray. Using this lat-
ter approach, the authors detected 667 miRNAs from one control
andoneADsubject (note thatmore than2,000humanmiRNAs are
currently registered in the miRNA database – www.mirbase.org).
The authors speciﬁcally quantiﬁed and validated changes in neu-
ronal miR-802, a suppressor of caveolin-1 (Lin et al., 2011), in the
CSF of control (n = 8) and AD (n = 14) patients. Clinical tests,
combined with Aβ42, t-tau, and p-tau-181 measurements in the
CSF were globally consistent with the diagnosis of either group.
Whether other miRNAs were misregulated in AD conditions was
not evaluated.
Only recently have two critical questions been addressed in
relation to CSF miRNAs in neurodegenerative diseases. The ﬁrst
natural question relates to why miRNAs are stably present in this
bioﬂuid. After all, RNAs are notoriously unstable in solution, and
yet there presence has been reliably afﬁrmed. Thus, there is a tanta-
lizing possibility that themiRNAs in solution – and in biochemical
packaging as described above – may be playing a role in the CNS.
In an elegant study, Lehmann et al. (2012) demonstrated that cir-
culating miRNAs, and in particular let-7b, could exacerbate brain
damage and neurodegeneration by binding directly to the Toll-
like receptor 7 (TLR7). As measured by miRNA qRT-PCR, AD
CSF (n = 13) contained signiﬁcantly higher levels of let-7b when
compared to controls (n = 11). Here, AD patients were selected, in
part, on the basis of Aβ42 and t-tau levels. Unfortunately, no cor-
relation between these AD markers and let-7b levels was provided.
However, this study demonstrates that miRNAs in CNS are bioac-
tive, and may have paracrine/hormonal-like functions, which, if
generally true, provides a novel and potentially incredibly impor-
tant context for miRNA function (and pathological impact) in the
brain.
A second key question is more practical, and was addressed by
Alexandrov et al. (2012): is there a correlation between Aβ pep-
tides and miRNA levels in the CSF? In this study, the patient
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groups consisted of six AD and six age-matched controls. Consis-
tent with previous studies using enzyme-linked immunosorbent
assay (ELISA), they reported a decrease in Aβ40 and Aβ42 in
AD CSF, although this observation did not reach statistical sig-
niﬁcance (P ∼ 0.06). Interestingly, the authors measured higher
(greater than 100-fold) levels of total miRNAs (total mass) when
compared to Aβ peptides, and this, both in control and AD CSF.
Fluorescence-based miRNA microarrays indicated that the pro-
inﬂammatorymiRNAsmiR-9,miR-125b,miR-146a, andmiR-155
were signiﬁcantly increased in AD CSF. These observations were
further validated by a highly sensitive light-emitting diode (LED)-
basedNortherndot-blot analysis. This increase of speciﬁcmiRNAs
was extended to in vitro paradigms, where primary human neu-
ronal/glial cells treated with AD-derived extracellular ﬂuid lead
to an increase of the same set of miRNAs. Signiﬁcant negative
correlations were observed between Aβ42 peptides and miR-137
(r = −0.75, P = 0.003), miR-181c (r = –0.57, P = 0.037),
miR-9 (r = –0.7, P = 0.007), miR-29a (r = –0.64, P = 0.01),
and miR-29b-1 (r = –0.569, P = 0.037), and this, in both
control and AD patients. Based on these observations, it is
tempting to speculate that miRs, alone or in combination with
known AD biomarkers, could provide a better assessment of AD
diagnosis.
BLOOD
Blood circulates in the principal vascular system, composed
of arteries and veins, to carry oxygen to and carbon dioxide
from tissues. The combination of lymphocytes, monocytes, and
macrophages composes the peripheral blood mononuclear cells
(PBMCs) population. These blood cells are critical components in
the immune system.
Schipper (2007) assessed miRNA levels in blood mononuclear
cells (BMCs) derived from sporadic AD and age-matched con-
trols (n = 16 per group), using a microarray chip containing 462
human miRNAs. Several miRNAs were identiﬁed to be signiﬁ-
cantly altered in AD BMCs. A large number of miRNAs, including
miR-34a, miR-181b, and let-7f, were validated by miRNA qRT-
PCR. Interestingly, miR-34 targets include p53 (He et al., 2007),
Notch (Bu et al., 2013), and Bcl-2 (Cole et al., 2008). The let-7
targets the oncogene Ras protein, thus promoting tumorigenesis
(Johnson et al., 2005). Inversely, let-7 expression is regulated by
the oncogenic Myc protein (Chang et al., 2008), suggesting a reg-
ulatory feedback loop. Together, these observations highlight the
importance of these miRNAs in cell/tissue homeostasis.
Geekiyanage and Chan (2011) showed by miRNA qRT-PCR a
decrease in miR-137, miR-181c, miR-9, and miR-29a/b levels in
the neocortical region of controls (n = 7) andAD subjects (n = 7),
which negatively correlatedwithAβ42 levels in post-mortembrain
tissues. In a follow-up study, using the same technical approach,
the group reported that the same miRNAs were also present in
the blood, albeit at lower basal levels (Geekiyanage et al., 2012).
They were found to be downregulated in the blood serum of mild
cognitive impairment (MCI; n = 7) and “probable” AD patients
(n = 7) when compared controls (n = 7).
Villa et al. (2013) provided further evidence that dysregulation
of peripheral miRNAs might contribute to AD development. In
isolated PBMCs, they ﬁrst showed that the transcription factor Sp1
was regulated at a post-transcriptional level by miR-29b. Interest-
ingly, Sp1 regulates the expression of AD-related genes such as
APP (La Fauci et al., 1989) and tau (Heicklen-Klein and Ginzburg,
2000). In a cohort of 393 AD patients and 412 healthy controls,
the group observed an inverse relationship between Sp1 mRNA
and miR-29b levels in PBMCs (p = 0.002). To our knowledge,
this is the ﬁrst report suggesting that changes in miRNA lev-
els (e.g., miR-29b) and its/their target(s) (e.g., Sp1) may serve
as cooperative biomarkers for AD diagnosis. Whether a genuine
interaction between both molecules occurs in the blood remains
to be validated.
Very recently, Bekris et al. (2013) reported in an elegant 3-phase
study including post-mortem brain arrays and qRT-PCR valida-
tion that plasmamiR-15a correlatedwith neuritic plaque score and
Braak stages in AD. This particular miRNA was predicted to mod-
ulate 9 AD-relevant genes, including APP (Liu et al., 2012) and tau
(Hebert et al., 2010). The authors concluded that pathologically-
altered brain miRNAs might be detected in CSF or plasma during
life, providing further proof of principle that miRNAs are relevant
clinical biomarkers of AD pathology.
CIRCULATING miRNA BIOMARKERS IN MILD COGNITIVE
IMPAIRMENT, AND CHALLENGES IN PATHOLOGICAL
SPECIFICITY
Mild cognitive impairment is a term often conﬂated with indi-
cating early clinical manifestation of AD, and many do indeed
progress to full-blownADclinically, althoughmanyother patholo-
gies than AD underlie the clinical state of MCI (see below).
Nevertheless, it is essential to develop tools that can accurately
discriminate between normal aging, MCI, AD, and likely other
cognitive disabilities. An attractive approachhas recently beenpro-
posed, namely miRNA“pairs.” This concept uses, following single
qRT-PCR TaqMan assays, bioinformatics to analyze the ratios of
all measured miRNAs, and select the most promising pair(s) of
biomarkers (Sheinerman et al., 2012). In a pilot study, 13 miRNA
pairs allowed to discriminate between AD and age-matched con-
trols, as well as between MCI and age-matched controls (n = 10
per group), and this, with up to 90% accuracy. The proposed sets
of miRNAs could detect pre-symptomatic MCI 1–5 years before
the diagnosis in 70% of cases. Finally, the same pairs of miRNAs
have been able to discriminate between aged and young healthy
controls (n = 20 per group).
There are two practical issues that are important to the clinical
relevance of any biomarker: sensitivity and speciﬁcity. The issue
of sensitivity is basic and relates to the fact that by the time AD
is manifest as MCI, it may be too late for (at least some) ther-
apeutic interventions. The Aβ/tau CSF studies have now shown
that, as expected (Nelson et al., 2009), up to one-third of non-
demented subjects harbor someAD-type pathology (Nelson et al.,
2012). It is increasingly appreciated that these are the patients
that should be targeted for biomarker studies as well as clinical
trials.
Aspects of biomarker speciﬁcity are perhaps paramount, and
often under-appreciated. Although MCI is often used to indicate
an early stage of AD, MCI was originally deﬁned according to
neuropsychological features (Portet et al., 2006), which have been
recognized to entail “multiple sources of heterogeneity.”As such, it
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is quite usual forMCI to be associatedwith brain pathologies other
than AD: dementia with Lewy bodies (DLB), vascular pathologies,
hippocampal sclerosis (HS-Aging), frontotemporal lobar demen-
tia (FTLD), and other conditions may cause or contribute to MCI,
as to dementia (Jicha et al., 2006). This highlights an important
aspect of AD-related biomarkers: they are not only used in pre-
dictingwhomwill becomedemented, but also for specifyingwhich
subtype of dementia will be predominant; the importance of this
speciﬁcity for clinical trials is obvious. Novel insights, relevant
to this consideration, were obtained by deep sequencing miRNAs
from brains of individuals with multiple different pathological
diseases (AD, DLB, FTLD, and HS-Aging; Hebert et al., 2013).
Although not a biomarker study per se, this showed that some
miRNAs (particularly miR-132-5p) are downregulated in neu-
rodegenerative diseases non-speciﬁcally. In the future, it is hoped
that more speciﬁc miRNA “ﬁngerprints” may help to distinguish
the individual subtypes of neurodegenerative diseases before their
earliest manifestations.
CONCLUSION AND PERSPECTIVES
To date, most researchers have relied on the combination of Aβ
peptides, total-tau, and phospho-tau (Thr181) ratios to provide
the best discriminative values for individuals with or without
AD. However, in most cases, large variability and differences
between studied groups did not reach statistical signiﬁcance,
leaving inconsistencies. Without excluding the amyloid and tau
biological markers, a combination of biomarkers may provide a
better tool for AD diagnosis, therefore improving their clinical
usefulness. Known examples include structural (e.g., hippocampal
shrinkage), functional (e.g., glucose metabolism), and molecular
imaging (e.g., ﬂuorescent Pittsburgh compound B; Chintamaneni
and Bhaskar, 2012).
Small non-coding RNAs, and in particular miRNAs, have
come a long way in the past two decades. As discussed herein,
circulating miRNAs provide an exciting and emerging research
area in the biomarker ﬁeld. As of now, long lists of miRNAs
potentially misregulated in disease conditions have been reported,
although ﬁnding overlaps is challenging (note that this is also
the case for miRNA proﬁling studies in the brain). How-
ever, some AD-speciﬁc miRNAs were “consistently” identiﬁed,
including some let-7 family members (let-7f, let-7b, and let-
7i), miR-9, miR-181, and miR-29 (Maes et al., 2009). These
miRNAs seem involved in processes previously associated with
AD, that is to say inﬂammation and immunological response.
Perhaps expectedly, several miRNAs and their functions as
biomarkers have been patented or in the process thereof (see,
e.g., www.freepatentsonline.com or www.patentlawlinks.com).
Although very attractive, the applicability of miRNAs as diagnos-
tic tools into the clinic for AD (or MCI) will require extensive
validation and follow-up studies in larger cohorts of patients.
This is important as AD is a heterogeneous, multifactorial dis-
ease, with often display overlapping pathologies (e.g., Aβ deposits
and Lewy bodies; Gomperts et al., 2008) and/or co-morbid diag-
noses (e.g., diabetes, stroke). Obviously, the ultimate goal is
to provide a sensitive, reproducible, and accurate detection of
AD neuropathological changes prior to the onset of the dis-
ease and the appearance of the clinical symptoms. To this end,
future studies will require better neuropathological validations as
well as, ultimately, far greater sample sizes for robust statistical
power.
In conclusion, circulating miRNAs are amongst the promising
next generation of biomarkers for AD, and ultimately the discrim-
ination between neurodegenerative diseases. They may be small
molecules, but miRNAs certainly provide a big potential for the
diagnosis of human diseases.
Note: While this work was in progress, a report has been
published with regards to a circulating miRNA signature in AD
patients (Leidinger et al., 2013).
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